Conclusion
At present, there is no consensus or published guidelines on ECMO
management in the sickle cell patient population; hence, there are no
recommendations for this patient population with SARS-CoV-2 infection.
With no immediate end in sight for the ongoing pandemic, any new
information that can shed a light on clinical management of sickle cell
patients with SARS-CoV-2 infection is greatly needed. Despite having SCD
and SARS-CoV-2, our patient was supported on VV-ECMO for 71 days with a
favorable outcome and without thrombosis, bleeding, pulmonary
hypertension, end organ dysfunction, or sepsis as a bridge to recovery
through a comprehensive multidisciplinary team effort.